• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Proactive news headlines including Altamira Gold, AIM ImmunoTech, QC Copper and Gold and Cloud Nine Education

    3/8/21 2:36:14 PM ET
    $TCON
    $ORGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TCON alert in real time by email

    New York, March 08, 2021 (GLOBE NEWSWIRE) -- - Altamira Gold Corp (CVE:ALTA) (OTCPINK:EQTRF) (FRA:T6UP) reveals four high-grade gold and silver vein structures at its Apiacas project in Brazil click here

    - Orgenesis Inc (NASDAQ:ORGS) (FRA:45O) teams with Dong-a University Hospital in South Korea and Cure Therapeutics to utilize its Mobile Processing Units and Labs, or OMPULs click here

    - QC Copper and Gold Inc (CVE:QCCU) (OTCMKTS:QCCUF) updates on Opemiska drill progress and names new independent director click here

    - AIM ImmunoTech Inc (NYSEAMERICAN:AIM) doses first healthy subject in intranasal Ampligen coronavirus study click here

    - Alpine 4 Technologies Inc (OTCQB:ALPP) says subsidiaries Deluxe Sheet Metal and Morris Sheet Metal merging to become one of the largest Midwest sheet metal contractors click here

    - BetterLife Pharma Inc (CSE:BETR) (OTCQB:BETRF) (FRA:NPAU) announces tie-up with Carleton University to study TD-0148A as treatment for depression click here

    - Cloud Nine Education Ltd (CSE:CNI) (OTCMKTS:CLGUF) launches new Education Technology Platform click here

    - Empower Clinics Inc (CSE:CBDT) (OTCQB:EPWCF) (FRA:8EC) says KAI LAB annual run rate now tops C$10M; plans to order 50,000 additional coronavirus tests click here

    - Orogen Royalties Inc (CVE:OGN) (OTCMKTS:EMRRF) (FRA:5EV)  to option Ecru gold project in Nevada to Australia's first all-female-led resources company, Moneghetti Minerals click here

    - Benchmark Metals Inc (CVE:BNCH) (OTCQB:CYRTF) (FRA:87CA)says latest Cliff Creek drill results bode well for upcoming resource estimate click here

    - Bam Bam Resources Corp (CSE:BBR) (OTCPINK:NPEZF) (FSE:4NPB) says drill findings show potential to expand known mineralization at Nevada project click here

    - KULR Technology Group Inc (OTCQB:KULR) announces new president and COO click here

    - CytoDyn Inc (OTCQB:CYDY) says Phase III trial shows safety, mortality reduction, and faster hospital discharge for COVID-19 patients treated with leronlimab click here

    - TechX Technologies Inc (CSE:TECX) (OTC:TECXF) (FRA:C0B) touts February growth of cryptocurrency exchange investee CatalX click here

    - Great Bear Resources Ltd (CVE:GBR) (OTCMKTS:GTBAF) appoints industry veteran Gilbert Lawson to its board of directors click here

    - Cloud Nine Education Group Ltd (CSE:CNI) (OTCMKTS:CLGUF) names entrepreneur and blockchain expert Pavel Bains as a strategic advisor click here

    - AgraFlora Organics International Inc (CSE:AGRA) (FRA:PU31) (OTCPINK:AGFAF) names Canadian cannabis industry veteran Elise Coppens as its new CEO and board director click here

    - TRACON Pharmaceuticals Inc (NASDAQ:TCON) appoints pharma executive Dr Lisa Johnson-Pratt to its board of directors click here

    About Proactive

    With six offices on three continents and a team of experienced business journalists and broadcasters, Proactive works with innovative growth companies quoted on the world’s major stock exchanges, helping executives engage intelligently with investors.

    Proactive’ s platform delivers the right message to the right audience, digitally and in real time, leveraging a range of media, investment research, digital investor targeting and website development services to support over 1,000 fast-growing companies globally.

    Proactive’s network reaches over 12 million engaged private, professional and institutional investors looking for opportunities.

    •           Our written and video content is published on Proactive sites that collectively attract up to 10 million views per month.

    •           We syndicate our content to hundreds of mainstream and specialist news sites that expand our reach into networks that can be difficult for press releases to penetrate.

    •           We custom build corporate websites from the ground up, empowering clients and their brands with a modern online presence and the latest insight on effective SEO strategy.

    •           Our news coverage ranks high on the world’s most popular search platforms, and we can further amplify online presence and outreach with sophisticated digital investor targeting.

    •           We help the world understand what makes companies stand out from the crowd with in-depth investment research from a team of experienced analysts.

    For more information on how Proactive can help you make a difference, email us at [email protected]


    Get the next $TCON alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TCON
    $ORGS

    CompanyDatePrice TargetRatingAnalyst
    TRACON Pharmaceuticals Inc.
    $TCON
    2/23/2022$10.00Outperform
    Baird
    More analyst ratings

    $TCON
    $ORGS
    SEC Filings

    See more
    • SEC Form 25-NSE filed by Orgenesis Inc.

      25-NSE - Orgenesis Inc. (0001460602) (Subject)

      5/8/25 5:21:49 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Orgenesis Inc. filed SEC Form 8-K: Other Events

      8-K - Orgenesis Inc. (0001460602) (Filer)

      4/22/25 4:30:38 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form NT 10-K filed by Orgenesis Inc.

      NT 10-K - Orgenesis Inc. (0001460602) (Filer)

      4/1/25 4:05:18 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TCON
    $ORGS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Orgenesis Provides Third Quarter 2024 Business Update

      GERMANTOWN, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (OTCQX: ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today provided a business update for the third quarter ended September 30, 2024. Vered Caplan, CEO of Orgenesis, stated, "Orgenesis is making significant progress in redefining accessibility to cell and gene therapies through our decentralized approach. This model is designed to expedite capacity setup, enhance production efficiency, and reduce treatment costs. We are dedicated to expanding our clinical initiatives and deepening gl

      11/13/24 8:00:00 AM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Orgenesis Commences Trading on OTCQX® Best Market

      Reports Plans to Reapply for Nasdaq Listing Announces Progress Advancing Decentralized Cell Processing Platform GERMANTOWN, Md., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today announced that its common stock will begin trading on the OTCQX® Best Market under the ticker symbol "ORGS" following its delisting from the Nasdaq Stock Market. The delisting resulted from the Company's failure to meet the required stockholders' equity threshold. Orgenesis plans to attempt to resolve the deficienc

      10/21/24 8:00:00 AM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Orgenesis Announces Reverse Stock Split

      GERMANTOWN, Md., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company") today announced that its Board of Directors has approved a 1-for-10 reverse stock split of the Company's common stock, par value $0.0001, which will be effective at 5:00 pm Eastern Time on September 24, 2024. The Company's common stock will continue to be traded on The Nasdaq Capital Market on a split-adjusted basis beginning on September 25, 2024, under the Company's existing trading symbol "ORGS". The reverse stock split is intended to regain compliance with the minimum bid price requirement of $1.00 per share of the Company's common stock for continued listing on The Nasdaq C

      9/23/24 7:00:00 AM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TCON
    $ORGS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Safier Jacob bought $16,883 worth of shares (30,000 units at $0.56) and sold $16,259 worth of shares (30,000 units at $0.54) (SEC Form 4)

      4 - Orgenesis Inc. (0001460602) (Issuer)

      12/4/24 6:48:38 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Safier Jacob bought $3,332 worth of shares (10,100 units at $0.33) (SEC Form 4)

      4 - Orgenesis Inc. (0001460602) (Issuer)

      2/14/24 9:32:21 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Safier Jacob bought $213,280 worth of shares (365,140 units at $0.58) (SEC Form 4)

      4 - Orgenesis Inc. (0001460602) (Issuer)

      2/14/24 9:31:52 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TCON
    $ORGS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Baird initiated coverage on TRACON Pharmaceuticals with a new price target

      Baird initiated coverage of TRACON Pharmaceuticals with a rating of Outperform and set a new price target of $10.00

      2/23/22 4:50:05 AM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alliance Global Partners initiated coverage on TRACON Pharmaceuticals with a new price target

      Alliance Global Partners initiated coverage of TRACON Pharmaceuticals with a rating of Buy and set a new price target of $13.00

      6/4/21 8:08:23 AM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tracon Pharmaceuticals upgraded by BTIG Research with a new price target

      BTIG Research upgraded Tracon Pharmaceuticals from Neutral to Buy and set a new price target of $14.00

      4/16/21 8:36:58 AM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCON
    $ORGS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $TCON
    $ORGS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form SC 13G/A filed by Orgenesis Inc.

      SC 13G/A - Orgenesis Inc. (0001460602) (Subject)

      12/4/24 6:51:18 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Orgenesis Inc.

      SC 13G/A - Orgenesis Inc. (0001460602) (Subject)

      12/4/24 6:50:26 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by TRACON Pharmaceuticals Inc.

      SC 13G/A - Tracon Pharmaceuticals, Inc. (0001394319) (Subject)

      11/14/24 8:51:58 PM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Malik Ariel claimed ownership of 1,200,000 shares (SEC Form 3)

      3 - Orgenesis Inc. (0001460602) (Issuer)

      3/18/25 4:06:38 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Vider Itzhak

      4 - Orgenesis Inc. (0001460602) (Issuer)

      12/16/24 2:42:24 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Adler Yaron

      4 - Orgenesis Inc. (0001460602) (Issuer)

      12/16/24 2:42:29 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TCON
    $ORGS
    Leadership Updates

    Live Leadership Updates

    See more
    • TRACON Pharmaceuticals Announces it Will Wind Down Operations

      SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (OTCQB:TCON) today announced that the Company has terminated its employees and will wind down its operations. This decision was made at a special meeting of the board of directors.  The board of directors appointed Craig R. Jalbert, age 62, as the Company's CEO, President, Treasurer and Secretary, and sole member of the board. Mr. Jalbert has served as a principal of the Foxborough, Massachusetts accounting firm of Verdolino & Lowey, P.C. since 1987. For over 30 years he has focused his practice in distressed businesses and has served, and continues to serve, in the capacities of officer and director for numerous firms in

      7/30/24 4:44:46 PM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cell and Gene Therapy Industry Pioneer & GMP Expert, Gerhard Bauer, Joins Orgenesis Business, Octomera, to Drive Continued Expansion of POCare Facilities and Service Support

      GERMANTOWN, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Orgenesis, a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), continues to grow the infrastructure of the advanced therapeutic POCare services and facilities supply business, Octomera. The appointment of Gerhard Bauer as the Vice President of Global Product Implementation at Octomera has been made to enhance the existing process development, regulatory, engineering, equipment, and data/technical service offering and POCare Center hubs. He is also an active contributor to the evolution of the flexible facilities format, Octomera Mobile Process Labs & Units (OMPULs) and network, which allow the

      9/6/23 7:00:00 AM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Orgenesis Appoints Finance Veteran Elliot Maltz as its Chief Financial Officer

      GERMANTOWN, Md., July 13, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) at the point of care, today announced the appointment of Elliot Maltz as Chief Financial Officer, effective September 1, 2023. Mr. Maltz succeeds Mr. Neil Reithinger, who is resigning following years of dedicated service and will remain with the Company until he completes his transition of duties, through September 1, 2023. Mr. Maltz brings 16 years of accounting and corporate finance experience working with public and private companies, specializing in the biotechnology, medical devic

      7/13/23 8:30:00 AM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TCON
    $ORGS
    Financials

    Live finance-specific insights

    See more
    • Orgenesis Provides Second Quarter 2024 Business Update

      GERMANTOWN, Md., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today provided a business update for the second quarter ended June 30, 2024. Vered Caplan, CEO of Orgenesis, stated, "After more than a decade of parallel efforts—on one hand, establishing robust capabilities in cell therapy production by initially serving the industry in a centralized manner and later integrating these capabilities into a decentralized platform, and on the other, forming partnerships through joint ve

      8/8/24 4:05:00 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

      SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (NASDAQ:TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the first quarter ended March 31, 2024. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific Time. "With ENVASARC fully enrolled we are focused on leveraging our Product Development Platform to generate non-dilutive capital through either an additional license or by replacing a CRO and executi

      5/14/24 4:01:00 PM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024

      SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (NASDAQ:TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its first quarter 2024 financial and operating results after the close of U.S. financial markets on Tuesday, May 14, 2024. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results. Date:May 14, 2024Time:4:30 pm Eastern Time (1:30 pm Pacific Time)Conference Call:In order t

      5/7/24 4:01:00 PM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care